The Sant’Orsola-Malpighi Polyclinic is a university and public hospital. The Polyclinc is the largest hospital in Italy, and the first of the four public hospitals of the city of Bologna. The Polyclinic has approximately 1,535 beds and 5,153 employees.

There are 1,535 beds in IRCCS - AOU di Bologna.

During the past decade, IRCCS - AOU di Bologna conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IRCCS - AOU di Bologna" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "IRCCS Azienda Ospedaliero-Universitaria di Bologna" with 5 trials sponsored, "Loxo Oncology, Inc." with 3 trials sponsored, "Pfizer" with 2 trials sponsored and "Bristol-Myers Squibb" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IRCCS - AOU di Bologna" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "BioMérieux" with 1 trials as a collaborator, "Loxo Oncology, Inc." with 1 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator and "Regina Elena Cancer Institute" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "IRCCS - AOU di Bologna" are "Multiple Myeloma" (3 trials), "Lymphoma, Mantle-Cell" (2 trials), "Non-Small Cell Lung Cancer" (2 trials), "Acute Kidney Injury" (1 trials) and "B-cell Lymphoma" (1 trials). Many other conditions were trialed in "IRCCS - AOU di Bologna" in a lesser frequency.

Most popular intervention types in "IRCCS - AOU di Bologna" are "Drug" (12 trials), "Other" (2 trials), "Radiation" (2 trials), "Behavioral" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pirtobrutinib" (3 trials), "Carboplatin" (2 trials), "Cisplatin" (2 trials), "Elranatamab" (2 trials) and "Pemetrexed" (2 trials). Other intervention names were less common.

The vast majority of trials in "IRCCS - AOU di Bologna" are 18 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "IRCCS - AOU di Bologna". undefined are not yet recruiting, 11 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in IRCCS - AOU di Bologna, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in IRCCS - AOU di Bologna, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".